Latest findings on advans breast cancer - Lɛ wi tɔk

If yu ɔ pɔrsin wae yu sabi de fɛt wit bɔrku kansa wae dɔn pasmak, e kin bi big tin fɔ gɛt trɛnk fɔ no bɔt nyu infɔmeshɔn ɛn tin dɛm wae yu dɔn fɛn. Sayɛnsman ɛn dɔktɔ dɛn kin tray ɔltɛm fɔ ɔndastand dis sik mɔ ɛn fɛn nyu tritmɛnt dɛn we go wok fayn . So lɛ wi tek tɛm luk wetin na dis nyu op.

Nyu drɔgs dɛn we dɛn dɔn gri fɔ

Dɛn dɔn ɔlrɛdi kam wit bɔku nyu mɛrɛsin dɛn we dɔn sho se dɛn dɔn rili wok fayn fɔ mek dɛn gɛt bɔdi kansa we dɔn go bifo. Sɔm pan dɛn tin ya kin wok bay we dɛn de tɔch sɔm patikyula prɔtin dɛn we de kɔntrol aw di kansa sɛl dɛn de gro.

Fɔ tɔk am simpul wan, sɔm kayn kansa na di bɔdi kin gɛt di ɔmon dɛn we de na di bɔdi fɔ mek i gro. wi kכl dεn "hכmon-rεsεptor positifu" kεnsar dεm. כlso, sכm kεnsar sεl dεm nכ gεt wan protin we dεn kכl `HER2` na dεn sεf. dεn kכl dεm ya `HER2` nεgεtiv kεnsar dεm. If yu gɛt dis kayn kansa, nyu mɛrɛsin kin bi fayn tin fɔ yu.

Lɛ wi tek wan luk pan sɔm pan dɛn nyu mɛrɛsin ya na di tebul we de dɔŋ ya.

Nyu op dɛm we stil de na di risach stej

Apat frɔm di mɛrɛsin dɛn we dɛn dɔn gri fɔ naw, bɔku ɔda mɛrɛsin dɛn de we go mek dɛn gɛt prɔmis we dɛn de du risach bɔt. Pan ɔl we dɛn nɔ de yuz dɛn tin ya yet, dɛn kin bi big blɛsin to wi tumara bambay.

PARP Inhibitɔ dɛn

dis dכg dεm de wok bay we dεn de blכk di abiliti fכ di kεnsar sεl dεm fכ ripa dεm sεf (DNA ripa). Dɛn dɔn si se dɛn kin rili yus fɔ pipul dɛn we gɛt muteshon na di jin dɛm we dɛn kɔl BRCA1 ɔ BRCA2, we gɛt fɔ du wit brɔst kansa.

Tayrosin kinaz Inhibitɔ dɛn

Dɛn mɛrɛsin ya bak we de blok di ɛnzaym dɛn we de ɛp di kansa sɛl dɛn fɔ gro. Dɛn dɔn ɔlrɛdi gri fɔ yuz lapatinib (Tykerb) fɔ HER2-positiv kansa. Wan ɔda mɛrɛsin we dɛn kɔl Neratinib, dɛn dɔn sho insay wan nyu stɔdi fɔ ɛp di wan dɛn we sik fɔ liv lɔng we dɛn gi am afta dɛn dɔn tek di kemotɛrapi.

Mɔ targeted HER2 tɛrapi dɛn

Na lɛk wan pan ɛvri fayv pipul dɛn we gɛt bɔdi kansa gɛt tumɔs pan wan prɔtin we dɛn kɔl HER2, we de ɛp fɔ mek di bɔdi kansa sɛl dɛn gro. Dɛn de mek drɔgs dɛn we de tɔch dis prɔtin ɛvride. Fɔ ɛgzampul, di drɔg we dɛn kɔl Margetuximab dɔn sho fayn fayn tin dɛn fɔ mek di tumbu dɛn nɔ bɔku, ɛn di mɛrɛsin we dɛn kɔl ONT-380 dɔn sho se i gɛt prɔmis fɔ trit bɔdi kansa wit smɔl sayd ɛfɛkt dɛn.

Ɔda imyunotɛrapi

Dɛn mɛrɛsin ya de wok bay we dɛn de mek wi yon imyun sistɛm ebul fɔ fɛt kansa. Di drɔg `Pembrolizumab` dɔn sho prɔmis rizɔlt insay klinik trial, mɔ as tritmɛnt fɔ di mɔ agresiv `Triple-Negative` kayn brɔst kansa.

Nyu ɔndastandin bɔt aw kansa kin skata

Apat frɔm dɛn nyu mɛrɛsin ya, sayɛnsman dɛn de fɛn nyu tin dɛn bak bɔt aw kansa kin skata ɔlsay na di bɔdi (mɛtastasis). Dis ɔndastandin rili impɔtant fɔ di tritmɛnt dɛn we dɛn go gɛt tumara bambay.

Imajin, wi bin de tink se kansa kin skata lɛk sojaman we kɔmɔt na ami we de kɔmɔt na di ami ɛn mek kamp na nyu ples. Dat min se wan kansa sɛl de travul tru di blɔd ɛn travul go na ɔda ɔgan lɛk di liva ɔ di lɔng.

Dis tin we dɛn dɔn fɛn rili impɔtant bikɔs, we wi dɔn no gud gud wan aw kansa de biev, i go izi fɔ sayɛnsman dɛn fɔ mek mɔ tritmɛnt dɛn we dɛn dɔn tɔk bɔt we go ebul fɔ stɔp dɛn grup dɛn de. Dat min se fɔ stɔp wan grup fɔ muv kin wok fayn pas fɔ stɔp wan sɛl.

Aw yu go ɛp fɔ du dis waka?

Wit dis nyu diskovri, yu tu kin get chans fo kontribiut fo dis fait fo som we.

Di tin we impɔtant pas ɔl na fɔ tɔk to yu dɔktɔ . Aks, "Ɛni nyu tritmɛnt ɔ klinik trial de na wi kɔntri we go rayt fɔ mi?" Klinik trial na stɔdi dɛn we dɛn de wach gud gud wan we de tɛst di ɛfɛktiv ɛn sef fɔ nyu drɔgs bifo dɛn gi dɛn to di jenɛral pɔblik.

Yu dɔktɔ go ebul fɔ ɛksplen di bɛnifit dɛn, di prɔblɛm dɛn, ɛn di tin dɛn we yu go op fɔ tek pat pan dis kayn trial. I impɔtant fɔ go to yu dɔktɔ bifo yu disayd fɔ du ɛnitin.

Dɔn bak, luk insay sɔpɔt grup fɔ di wan dɛn we gɛt kansa. Dɛn kin gi yu sɔpɔt pan aw yu de fil ɛn nyu tin dɛn. Mɛmba se nɔto yu wangren de du dis waka.